Top Markets
Coin of the day
Enimmune corporation Enimmune corporation

Enimmune corporation

6564
Clasificación en acciones #26782
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Precio por acción
$0.52468396
Capitalización bursátil
$37.85M
Cambio (1 día)
1.23%
Cambio (1 año)
-4.53%
País
TW
Comercio Enimmune corporation (6564)

Categoría

Ganancias de Enimmune corporation (6564)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Enimmune corporation, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Enimmune corporation desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
$-3.09B -
US
- -
CH